Shanghai Hile Bio-tech (603718) - Total Liabilities
Based on the latest financial reports, Shanghai Hile Bio-tech (603718) has total liabilities worth CN¥312.90 Million CNY (≈ $45.79 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Shanghai Hile Bio-tech to track the company's year-over-year net asset growth rate.
Shanghai Hile Bio-tech - Total Liabilities Trend (2011–2025)
This chart illustrates how Shanghai Hile Bio-tech's total liabilities have evolved over time, based on quarterly financial data. See Shanghai Hile Bio-tech (603718) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Shanghai Hile Bio-tech Competitors by Total Liabilities
The table below lists competitors of Shanghai Hile Bio-tech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TWFG, Inc. Class A Common Stock
NASDAQ:TWFG
|
USA | $53.43 Million |
|
Huaiji Dengyun Auto-parts Holding Co Ltd
SHE:002715
|
China | CN¥373.18 Million |
|
Bangkok Land Public Company Limited
BK:BLAND-R
|
Thailand | ฿12.48 Billion |
|
Korea No. 9 Special Purpose Acquisition Co. Ltd.
KQ:368770
|
Korea | ₩24.53 Billion |
|
Shanghai Kaytune Industrial Co.Ltd
SHE:301001
|
China | CN¥87.89 Million |
|
Hangzhou Xili Intelligent Technology Co. Ltd. A
SHG:688616
|
China | CN¥182.40 Million |
|
Shanghai Lisheng Racing Co Ltd
SHE:002858
|
China | CN¥289.08 Million |
|
ZheJiang BangJie Digital Knitting Share Co Ltd
SHE:002634
|
China | CN¥3.08 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Shanghai Hile Bio-tech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Shanghai Hile Bio-tech.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Hile Bio-tech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Hile Bio-tech (2011–2025)
The table below shows the annual total liabilities of Shanghai Hile Bio-tech from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥229.14 Million ≈ $33.53 Million |
+85.32% |
| 2024-12-31 | CN¥123.65 Million ≈ $18.09 Million |
-74.40% |
| 2023-12-31 | CN¥482.96 Million ≈ $70.67 Million |
+19.77% |
| 2022-12-31 | CN¥403.25 Million ≈ $59.01 Million |
-52.94% |
| 2021-12-31 | CN¥856.90 Million ≈ $125.39 Million |
+3.92% |
| 2020-12-31 | CN¥824.54 Million ≈ $120.66 Million |
+16.34% |
| 2019-12-31 | CN¥708.72 Million ≈ $103.71 Million |
-1.95% |
| 2018-12-31 | CN¥722.81 Million ≈ $105.77 Million |
+37.20% |
| 2017-12-31 | CN¥526.83 Million ≈ $77.09 Million |
+11.02% |
| 2016-12-31 | CN¥474.55 Million ≈ $69.44 Million |
+71.31% |
| 2015-12-31 | CN¥277.01 Million ≈ $40.54 Million |
+188.62% |
| 2014-12-31 | CN¥95.98 Million ≈ $14.04 Million |
-4.19% |
| 2013-12-31 | CN¥100.17 Million ≈ $14.66 Million |
+7.97% |
| 2012-12-31 | CN¥92.78 Million ≈ $13.58 Million |
-5.61% |
| 2011-12-31 | CN¥98.29 Million ≈ $14.38 Million |
-- |
About Shanghai Hile Bio-tech
Shanghai Hile Bio-Technology Co., Ltd. develops, manufactures, and sells in vitro diagnostic reagents and oral tissue repair and regeneration materials in China. It operates through two segments: In Vitro Diagnostic Reagents and Oral Tissue Repair and Regeneration Materials. The In Vitro Diagnostic Reagents segment offers biochemical diagnostic reagents, immuno-latex reagents, immune turbidimetry… Read more